Brainstorm secures key manufacturing partnership with minaris for upcoming nurown® phase 3b als clinical trials

New york , may 27, 2025 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has signed a letter of intent (loi) with minaris advanced therapies, a global contract development and manufacturing organization (cdmo) specializing in cell and gene therapies, to manufacture nurown® for its upcoming clinical trial. the loi marks the beginning of a strategic collaboration between brainstorm and minaris to initiate the technology transfer of nurown® in preparation for clinical trial manufacturing at minaris' state-of-the-art facility in allendale, new jersey.
BCLI Ratings Summary
BCLI Quant Ranking